Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Priority Review Voucher Plan's Looming Sunset Shouldn't Dissuade Sponsors – FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Although FDA will be barred from issuing new rare pediatric disease priority review vouchers in March absent a legislative extension, agency is still encouraging sponsors to file designation requests.


Related Content

Priority Review Vouchers: Buyers Beware!


Related Companies